Physician profile
Joseph D Bailey
NPI 1144510231
$1,944.06
in general payments reported to CMS, 2019-2025
28 companies · $153 in 2025
The $153 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $668 · 2020: $99.77 · 2021: $305 · 2022: $219 · 2023: $263 · 2024: $236 · 2025: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $652.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $651.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $517.22 | 2019-2025 | Vraylar |
| Glaxosmithkline, LLC. | $147.24 | 2019-2024 | Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $145.55 | 2019-2020 | |
| Pfizer INC. | $142.47 | 2019-2025 | |
| Novo Nordisk INC | $139.96 | 2019-2024 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $121.99 | 2019 | |
| Amgen INC. | $106.30 | 2021-2025 | Otezla, Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $100.78 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.67 | 2019-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $70.61 | 2019-2020 | |
| Lilly USA, LLC | $43.83 | 2022-2023 | Mounjaro, Emgality, Jardiance |
| Biohaven Pharmaceuticals, INC. | $36.18 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $35.19 | 2024 | Rexulti |
| Cranial Technologies, INC | $32.45 | 2019-2023 | Doc Band |
| Ultragenyx Pharmaceutical INC. | $29.63 | 2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $22.91 | 2022 | |
| Corcept Therapeutics | $20.30 | 2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $19.54 | 2025 | |
| Abbott Laboratories | $19.24 | 2021 | |
| Ironshore Pharmaceuticals INC. | $16.74 | 2020 | |
| Circassia INC. | $16.43 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.73 | 2023 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $13.69 | 2022 | |
| Dexcom, INC. | $13.23 | 2024 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $13.05 | 2019 | |
| Vanda Pharmaceuticals INC. | $12.16 | 2019 | |
| Sobi, INC | $12.00 | 2019 | |
| Dynavax Technologies Corporation | $6.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.